QIAGEN and GENEART Partner to Commercialize Synthetic Human Genes

Joint development and collaboration enables enhanced production of every human protein, spurring advances in drug development

15-May-2008

QIAGEN and GENEART announced their collaboration to develop, produce and commercialize a new product line for the enhanced production of all 35,000 human proteins. According to the company, QIAgenes is the world's first comprehensive set of plasmids (small extra-chromosomal DNA molecules in bacteria) which serve as carriers ("vectors") for modified ("optimized") synthetic genes mapping the entire human genome. By using the QIAgenes set of plasmids and optimized genes for synthetic protein production in bacteria, academic and biomedical researchers, as well as biotech and pharmaceutical companies can more easily produce large amounts of proteins which play key roles in diseases such as cancer and their treatment. This new product line enables researchers to facilitate the development of new therapeutics and vaccines and accelerates future drug screening processes.

The collaboration between QIAGEN and GENEART was initiated with a joint research and development project, for which GENEART provided plasmid and gene synthesis technologies and QIAGEN supplied automated sample technologies to purify the expressed proteins. In this first of a series of ongoing collaboration projects, scientists from both companies compared optimized and normal gene sequences of 100 different proteins from the five most common protein classes, thereby generating the most comprehensive validation study of its kind. The trial showed that QIAgenes solutions achieved very high success rates of more than 90% and yielded up to 50 times more protein than conventional methods using "normal" genes by providing optimized synthetic genes and purification methods.

https://www.bionity.com/en/news/82061/qiagen-and-geneart-partner-to-commercialize-synthetic-human-genes.html